Citations

Clear

9383 citation(s) found for "Thomas, PS".

Laparotomy for Presumed Ruptured Abdominal Aortic Aneurysm: Outcome of Deceptive Emergencies
Melin, Matthew M , Gloviczki, Péter , Cherry, Kenneth J., Bower, Thomas C., Hallett, John W., Baerga, Yvonne, Zietlow, Scott P., Stanson, Anthony W., Gloviczki, Péter

Mayo Clinic

Vascular Surgery | November 26, 2007 | Volume: 31 | Issue: 5 | Pages: 523-530

10.1177/153857449703100503 Get It

Medical and surgical emergencies occasionally present as ruptured abdominal aortic aneurysms (RAAA). To assess benefits of laparotomies and adverse effects of unnecessary operations, the authors reviewed their experience. Thirteen patients, 9 women, 4 men (mean age: 72 years, range: 41-85) underwent emergency laparotomy between 1988 and 1996 for presumed RAAA and were found to have other surgical or medical emergencies. All the patients presented with hypotension, 12 had abdominal or back pain, four had pulsatile abdominal mass. Rupture was not excluded by computed tomography scan in three or by ultrasonography in two patients. Laparotomy disclosed intact abdominal aorta in all, but seven patients had abdominal aortic aneurysm. Of five surgical emergencies, laparotomy was indicated in four: three for ruptured visceral artery aneurysms, one for perforated duodenal ulcer. The fifth patient required thoracotomy for ruptured thoracic aneurysm. Four of eight medical emergencies were myocardial infarctions. One iatro genic complication required reoperation for bleeding. Mean hospital stay was 18 days; mean hospital charges were $40,771. Seven (54%) early deaths occurred; none were caused directly by the operation. Laparotomy was indicated in one third of deceptive emergencies that present as RAAA. Although mortality, morbidity, and costs were high, iatrogenic surgical complica tions were rare and deaths were not caused by unnecessary operations.
The Case for Aggressive Treatment
Gloviczki, Péter , Canton, Linda G., Bower, Thomas C., Cherry, Kenneth J., Hallett, John W., Stanson, Anthony W., Pairolero, Peter C., Gloviczki, Péter

Mayo Clinic

Vascular Surgery | November 26, 2007 | Volume: 31 | Issue: 3 | Pages: 319-320

10.1177/153857449703100343 Get It

Congenital Neuroblastorna in the Scrotum
Simpson, Thomas, Lynn, Hugh B., Mills, Stephen D.

Mayo Clinic

Clinical Pediatrics | November 26, 2007 | Volume: 8 | Issue: 3 | Pages: 174-175

10.1177/000992286900800311 | PMID 5812722 Get It

Heat Stroke: Recognition and Principles of Management
Gottschalk, Paul G., Thomas, Juergen E.

Mayo Clinic

Clinical Pediatrics | November 26, 2007 | Volume: 6 | Issue: 10 | Pages: 576-578

10.1177/000992286700601010 | PMID 6061647 Get It

Solitary Fibrous Tumor of the Orbit
Lucas, David R. , Fletcher, Christopher D.�M. , Garrity, James A., McCartney, Alison, Bell, Chaim M. , Nascimento, Antonio G.

Mayo Clinic

International Journal of Surgical Pathology | November 26, 2007 | Volume: 2 | Issue: 3 | Pages: 193-198

10.1177/106689699500200304 Get It

We report three cases of solitary fibrous tumor (SFT) arising in the orbit. All patients presented with nontender swelling of the affected eye, and one patient presented with nasolacrimal duct obstruction. All three patients had well-circumscribed tumors that had histologic features identical to those of SFT of the pleura (fibrous mesothelioma). The neoplastic cells were purely fibrogenic. They were reactive with antivimentin and CD-34 and demonstrated no smooth muscle or neural differentiation (nonreactive with antibodies to actin, desmin, and S 100 protein). KP-1 (CD-68) immunoreactivity was present focally within the neoplastic cells in all three tumors; however, it was strongly positive within tumor infiltrating macrophages. Electron microscopy per formed on one tumor showed fine fibroblastic differentiation with phagocytic activity confined to infiltrating macrophages. SFT of the orbit is a distinct pathologic entity that merits distinction within the broad group of orbital fibrous tumors. Int J Surg Pathol 2(3):193-198, 1995
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Monti, Stefano , Juszczyński, Przemysław , Daley, John, Chen, Wen , Kutok, Jeffery L. , Chen, Lin‐Feng , Witzig, Thomas E. , Habermann, Thomas M. , Shipp, Margaret Ann

Mayo Clinic

Blood | November 15, 2007 | Volume: 111 | Issue: 4 | Pages: 2230-2237

10.1182/blood-2007-07-100115 | PMID 18006696 Get It

The role of B-cell receptor (BCR)–mediated survival signals in diffuse large B-cell lymphoma (DLBCL) remains undefined. Ligand-induced BCR signaling induces receptor oligomerization, Igα/β immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation, and activation of the spleen tyrosine kinase (SYK), which initiates downstream events and amplifies the initial BCR signal. BCRs also transmit low-level tonic survival signals in the absence of receptor engagement. Herein, we assess the role of SYK-dependent tonic BCR survival signals in DLBCL cell lines and primary tumors and evaluate the efficacy of an ATP-competitive inhibitor of SYK, R406, in vitro. R406 induced apoptosis of the majority of examined DLBCL cell lines. In R406-sensitive DLBCL cell lines, R406 specifically inhibited both tonic- and ligand-induced BCR signaling (autophosphorylation of SYK525/526 and SYK-dependent phosphorylation of the B-cell linker protein [BLNK]). The majority of examined primary DLBCLs also exhibited tonic- and ligand-induced BCR signaling; in these primary tumors, BCR signaling was also inhibited by R406. Of note, BCR-dependent and R406-sensitive DLBCL cell lines were independently identified as “BCR-type” tumors by transcriptional profiling. Therefore, SYK-dependent tonic BCR signaling is an important and potentially targetable survival pathway in some, but not all, DLBCLs. In addition, R406-sensitive DLBCLs can be identified by their transcriptional profiles.
Computed Tomography Findings in Pathological Usual Interstitial Pneumonia
Sumikawa, Hiromitsu , Johkoh, Takeshi , Colby, Thomas V. , Ichikado, Kazuya , Suga, Moritaka, Taniguchi, Hiroyuki , Ogura, Takashi , Arakawa, Hiroaki , Fujimoto, Kiminori , Inoue, Atsuo, Mihara, Naoki , Honda, Osamu, Nakamura, Hironobu, Müller, Néstor L. , Kondoh, Yasuhiro , Tomiyama, Noriyuki

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | November 1, 2007 | Volume: 177 | Issue: 4 | Pages: 433-439

10.1164/rccm.200611-1696oc | PMID 17975197 Get It

Abstract Rationale Patients with a clinicopathological diagnosis of idiopathic pulmonary fibrosis (IPF) may have typical findings of usual interstitial pneumonia (UIP) on computed tomography (CT) or nonspecific or atypical findings, including those often seen in nonspecific interstitial pneumonia. Objectives The aims of this study were to revisit the high-resolution CT findings of IPF and to clarify the correlation between the CT findings and mortality. Methods The study included 98 patients with a histologic diagnosis of UIP and a clinical diagnosis of IPF. Two observers evaluated the CT findings independently and classified each case into one of the following three categories: (1) definite UIP, (2) consistent with UIP, or (3) suggestive of alternative diagnosis. The correlation between the CT categories and mortality was evaluated using the Kaplan-Meier method and the log-rank test, as well as Cox proportional hazards regression models. Measurements and Main Results Thirty-three of the 98 CT scans were classified as definite UIP, 36 as consistent with UIP, 29 as suggestive of an alternative diagnosis. The mean survival was 45.7, 57.9, and 76.9 months, respectively. There was no significant difference in survival among the three categories (all P > 0.05). Traction bronchiectasis and fibrosis scores were significant predictors of outcome (hazard ratios: 1.30 and 1.10, respectively; 95% confidence intervals: 1.18–14.2 and 1.03–1.19, respectively). Conclusions In patients with IPF and UIP pattern on the biopsy, the pattern of abnormality on thin-section CT, whether characteristic of UIP or suggestive of alternative diagnosis, does not influence prognosis. Prognosis is influenced by traction bronchiectasis and fibrosis scores.
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Rajkumar, S. Vincent , Richardson, Paul G. , Lacy, Martha Q. , Dispenzieri, Angela , Greipp, Philip R., Schlossman, Robert, Sidor, Carolyn, Richardson, Paul Gerard Guy , Witzig, Thomas E. , Anderson, Kenneth C. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Clinical Cancer Research | October 18, 2007 | Volume: 13 | Issue: 20 | Pages: 6162-6167

10.1158/1078-0432.ccr-07-0807 | PMID 17947482 Get It

Abstract Purpose: 2-Methoxyestradiol (2ME2) is an endogenous product of estradiol metabolism with antiangiogenic and antineoplastic properties. We report on the first phase II trial of 2ME2 in multiple myeloma. Experimental Design: 2ME2 was administered orally at a dose of 1,000 mg daily. Sixty patients (31 men and 29 women) were treated. After 39 patients were accrued, the dose was increased to 800 mg twice daily for the remaining patients. Results: Thirty-one patients had relapsed or refractory multiple myeloma, and 29 had plateau phase multiple myeloma. Median age was 60 years (range, 27-84 years). Therapy was well tolerated. Common adverse events included anemia (35%), fatigue (35%), nausea (25%), diarrhea (20%), hot flushes (20%), headache (17%), muscle cramps (15%), and upper respiratory tract infection (15%). Most adverse events were mild (grade 1-2); 12% experienced grade 3-4 adverse events. Median time to progression was 3.8 months, with 5.6 months for plateau phase disease and 2.3 months for relapsed multiple myeloma. Estimated progression-free survival rates for all patients at 1, 2, and 3 years were 24%, 17%, and 11%, respectively. Three patients, all with plateau phase disease, have been on study for over 4 years without progression at 50, 60, and 63 months, respectively. Minor response was noted in 2 patients. Conclusions: Although no partial responses have been seen thus far, the minor responses and prolonged stable disease seen with 2ME2 therapy are promising. Plasma levels indicate that the dose of 2ME2 was inadequate. A new formulation with better bioavailability will be tested soon in multiple myeloma.